ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa(R) in various atrial fibrillation patient populations

INGELHEIM, Germany--(BUSINESS WIRE)-- Aug. 26, 2013 10:17 UTC --

For media outside of the US, the UK & Canada only

Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa(R) (dabigatran etexilate) during the ESC Congress 2013 organised by the European Society of Cardiology (August 31 - September 4, Amsterdam, The Netherlands). The new data will add to the already available extensive body of knowledge on Pradaxa(R)'s positive safety and efficacy profile.

Boehringer Ingelheim remains committed to advancing the cardiology field and supporting physicians in their search for optimal stroke protection. Data being presented at the ESC Congress 2013 will complement the ongoing clinical trial programme of Pradaxa(R), including results from the pivotal RE-LY(R) trial and the only long-term NOAC study, RELY-ABLE(R), as well as new preclinical research on the company's investigational antibody fragment antidote for dabigatran.

"The breadth of data being presented for Pradaxa(R) at this year's ESC Congress 2013 demonstrates Boehringer Ingelheim's continued dedication to improving the lives of patients with cardiovascular disorders. Our extensive and ongoing investment into clinical research will provide additional evidence on the positive efficacy and safety profile of Pradaxa(R) as well as important insights on its use in a wide range of patients and clinical settings", said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim.

Details of the key Pradaxa(R) abstracts being presented at the ESC Congress 2013 are listed below. Further information and the full list of abstracts can be found within the Scientific Programme, available at: http://spo.escardio.org/default.aspx?eevtid=60TITLEManagement of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LYLEAD AUTHORRobby Nieuwlaat (Hamilton, CA)DETAILSPoster Presentation ESC Number: P549Poster Session 1: Arrhythmias - Pacing - ResynchronisationDate: 31 AugustDisplay Time: 14:00-18:00Presentation Time: 15:30-16:30Location: Posters - Village 9TITLEEffects of the direct thrombin inhibitor dabigatran etexilate vs warfarin on platelet function in patients with atrial fibrillationLEAD AUTHORGiulia Renda (Chieti, IT)DETAILSPoster PresentationESC Number: P1430Poster Session 2: Treatment of HypertensionDate: 1 SeptemberDisplay Time: 08:30-12:30Presentation Time: 10:00-11:00Location: Posters - Village 9TITLERE-ALIGN: Dabigatran in patients with a mechanical heart valveLEAD AUTHORFrans Van de Werf (Leuven, BE)DETAILSHot Line PresentationESC Number: 937Hot Line 1: Late Breaking Trials on ThrombosisDate: 1 SeptemberTime: 11:54-12:06Location: Amsterdam - Central VillageTITLEGuidance adherent dabigatran etexilate treatment versus warfarin in the RE-LY population: an analysis on the basis of the European label recommendations for dabigatran etexilateLEAD AUTHORGregory Y H Lip (Birmingham, GB)DETAILSPoster PresentationESC Number: P4278Poster Session 5: Atrial Fibrillation: New InsightsDate: 2 SeptemberDisplay Time: 14:00-18:00Presentation Time: 15:30-16:30Location: Posters - Village 9TITLEReversal of dabigatran clotting activity in the rat ex vivo by a specific and selective antibody fragment antidote: are there non-specific effects on warfarin, rivaroxaban and apixaban?LEAD AUTHORJoanne Van Ryn (Biberach, DE)DETAILSPoster PresentationESC Number: P4848Poster Session 6: Thrombosis and Antithrombotic TherapyDate: 3 SeptemberDisplay Time: 08:30-12:30Presentation Time: 10:00-11:00Location: Posters - Village 9Pradaxa(R) is widely approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for primary prevention of VTE following total hip replacement or total knee replacement surgery.1 The extensive in-market experience of over 2 million patient-years in all licensed indications puts Pradaxa(R) first among the novel oral anticoagulants.2 In addition, Boehringer Ingelheim recently started submitting applications to regulatory authorities for the use of Pradaxa(R) in the acute treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism.

~ENDS~

Please click on the link below for 'Notes to Editors' and 'References': http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/26_august_2013_dabigatranetexilate.html

▲ Contacts

Boehringer Ingelheim GmbHSara McClellandCorporate CommunicationsMedia + PRPhone: +49 6132 - 77 8271Fax: + 49 - 6132 - 72 6601E-mail: press@boehringer-ingelheim.comTwitter: http://twitter.com/BoehringerorMore informationwww.boehringer-ingelheim.com

<저작권자ⓒ 공감언론 뉴시스통신사. 무단전재-재배포 금지.>